Ó³»­´«Ã½

Pan-Cancer Project brings researchers closer to identifying all major cancer-causing genetic mutations.

Study will help narrow down the list of targets for the next generation of cancer treatments

A computational model could improve the selection of tumor antigens for personalized cancer vaccines that are now in early-stage clinical trials.

The new tool more accurately distinguishes mutations that drive cancer from ones that don’t, and could help focus future research and drug development.

A clinical study comparing liquid and tissue biopsies finds multiple resistance mechanisms in individual patients, which could explain why targeted therapies often fail.

Analyzing RNA sequencing data pinpoints ‘somatic clones,’ including some harboring cancer mutations, in many types of normal tissue.

By matching cells' growth trajectories to their genetic features, a team finds CLL cells' arc of growth is written into their genes early in disease development.

By probing the molecular basis of proteasome inhibitor resistance in cancer cells, a Ó³»­´«Ã½-led team finds new vulnerability — and compounds that exploit it.